DelveInsight’s “Vitiligo – Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As per DelveInsight, the Vitiligo therapeutics market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases of Vitiligo, the rise in healthcare spending across the world, and the expected launch of drugs in the market. Some of the key companies in the Vitiligo therapeutics market include ICN Pharmaceuticals, Inc, Valeant Pharmaceuticals, Astellas Pharma, and others.
Vitiligo Overview
Vitiligo is a complex pigment disorder affecting the skin, hair, and occasionally the mucous membranes. It is a long-term condition characterized by the development of pale white patches on the skin, commonly appearing on the face, neck, and hands. Clinically, vitiligo manifests as milk-white, irregularly oval patches of skin that start small but gradually enlarge. The hair growing in the depigmented area also turns white. Vitiligo can be triggered by stress to the melanin-producing cells of the skin, known as melanocytes. Triggers such as sunburn, mechanical trauma, and chemical exposures can initiate an autoimmune response that targets melanocytes, leading to progressive skin depigmentation.
Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. Multiple mechanisms have been proposed for melanocyte destruction in vitiligo, including genetic factors, autoimmune responses, oxidative stress, the generation of inflammatory mediators, and melanocyte detachment mechanisms. Both innate and adaptive immunity play roles in the development of vitiligo.
Vitiligo Diagnosis
The diagnosis of vitiligo is primarily clinical, based on the patient’s history, clinical presentation, and family history (including vitiligo and other autoimmune disorders). Key clinical markers of active, progressive disease include Koebner’s phenomenon, trichrome lesions, inflammatory lesions, and confetti-like depigmentation.
Vitiligo Treatment
The optimal treatment of vitiligo depends on the subtype of the disease, the percentage of body surface area (BSA) involved, the impact on the patient’s quality of life, and the patient’s perception of the risk-to-benefit ratio. Treatments aim to stabilize depigmented lesions and stimulate repigmentation and include:
Vitiligo Medications and Topical Treatments:
-
Corticosteroids: Can help return color to white patches of skin.
-
Calcineurin Inhibitors: Also used to restore skin color.
-
Phototherapy:
-
Light Boxes: Used to treat large areas of vitiligo.
-
Laser Treatments: Used for more localized areas.
-
-
Depigmentation Therapy:
-
Removes the color of the natural skin tone to match areas affected by vitiligo.
-
Vitiligo Surgical Treatments:
-
Skin Grafts: Transplant healthy skin to affected areas.
-
Cell Transplants: Transfer melanocytes to depigmented areas.
-
Successful treatment for vitiligo incorporates three distinct approaches: reducing melanocyte stress, regulating the autoimmune response, and stimulating melanocyte regeneration. It is important to note that treatments may take time, and not everyone responds similarly. Results can vary from one part of the body to another, and new patches may appear during treatment. Often, doctors recommend combining multiple treatments to achieve the best results.
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Vitiligo and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Vitiligo market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule Type
The emerging pipeline products have been categorized under various Molecule types in the report, such as –
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
-
Janus kinase 1 inhibitor
-
Emt protein-tyrosine kinase inhibitors
-
TYK2 kinase inhibitors
-
Syk kinase inhibitors
-
Interleukin 15 inhibitors
-
HSP70 heat shock protein stimulants
-
IFN-γ antagonist
-
Melanocortin type 1 receptor modulators
Learn How the Ongoing Clinical & Commercial Activities will Affect the Vitiligo Therapeutic Segment @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight
Leading Companies in the Vitiligo Therapeutics Market Include:
-
Aclaris Therapeutics
-
Amgen
-
Arcutis Biotherapeutics
-
Arrien Pharmaceuticals
-
AXIM Biotechnologies
-
Bioniz Therapeutics
-
Boston Pharmaceuticals
-
Celgene
-
Clinuvel Pharmaceuticals
-
Dermavant Sciences
-
Incyte Corporation
-
Pfizer
-
Temprian Therapeutics
-
TWi Biotechnology
Vitiligo Emerging and Marketed Drugs Profile:
-
1BNZ-1: Bioniz Therapeutics
-
AC-1101: TWi Biotechnology
-
Afamelanotide: Clinuvel, Inc.
-
AMG-714: Amgen
-
ATI-1777: Aclaris Therapeutics
-
Cerdulatinib: Dermavant Sciences
-
PF-06651600: Pfizer
-
Phimelanotide – Clinuvel Pharmaceuticals
-
Ritlecitinib: Pfizer
-
Ruxolitinib: Incyte Corporation
-
TT-01: Temprian Therapeutics
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Vitiligo Current Treatment Patterns
4. Vitiligo – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Vitiligo Late Stage Products (Phase-III)
7. Vitiligo Mid-Stage Products (Phase-II)
8. Vitiligo Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Vitiligo Discontinued Products
13. Vitiligo Product Profiles
14. Key Companies in the Vitiligo Market
15. Key Products in the Vitiligo Therapeutics Segment
16. Dormant and Discontinued Products
17. Vitiligo Unmet Needs
18. Vitiligo Future Perspectives
19. Vitiligo Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/